X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Dr Reddy’s: A volatile story - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • Dec 9, 2004

    Dr Reddy’s: A volatile story

    Dr Reddy’s has been one of the most revered domestic pharmaceutical companies. The reverence for the company is due to its vision to be a research driven company and the company has been valued more than any other in the Indian pharma sector. Dr Reddy’s has been one of the first few companies in the country to enter in NCE (new chemical entity) research and spending a large proportion of its revenue on the same. Despite these positives, the stock of the company has been ‘hammered’ in recent times. Let us delve into the reasons for this volatility.

    The revenue front… Dr Reddy’s has been following a business strategy, which has subjected its revenues and profits to a high degree of volatility. Here, let us first understand the sources of revenue for the company. There are three major sources of revenue for Dr. Reddy’s –

    1. Formulations,

    2. APIs (active pharmaceutical ingredients), and

    3. Generics.

    Formulations and APIs are two stable sources of revenues for the company. However, the generics business has seen a high degree of volatility in terms of contribution to revenues (see graph below), much of which can be attributed to strategy followed by the company for this business segment. Dr Reddy’s believes in applications under Para IV, which means that if the company is successful in its application, it can witness a huge upside on both revenues and profits front as it happened in case of Fluoxetine. However, if the company loses the case, money spent on costly legal battle will affect its profitability, as was evident in the case of Amlodipine Maleate. Also, in case of Para IV successes, revenues tend to decline after the exclusivity period (six months) comes to an end as more competitors enter the market.

    The profitability front…
    The change in business mix towards increased contribution from APIs has severely impacted the profitability of Dr. Reddy’s as generics and formulations are more profitable as compared to the API business. Another factor that has affected profitability of Dr Reddy’s is higher SG&A (sales, general and administrative) expenses and R&D (research and development) expenses. For instance, the SG&A expenses have increased by 32% CAGR in the past four years, much higher compared to the 22% CAGR of revenues. Similar is the case with R&D expenditure which has risen with 40% CAGR during this period. The major increase in these expenses has come up in the last 5-6 quarters and we believe that the investment in SG&A expenses will have long-term implications, in terms of revving up the company’s distribution and marketing network in the US and other global generic markets. On the R&D front, the company has two major areas of work i.e. NCE and ANDA (abbreviated new drug application). While, off late, Dr. Reddy’s has increased its spending towards R&D on the ANDA front, the NCE research will take its time to reap any benefit.

    What to expect? We believe that the expenditure on SG&A and R&D fronts are in line with the long-term vision of the company. These expenses are actually investments for the future and the benefits are likely to accrue in the long run. We would like to quote Ranbaxy on this front, which invested heavily in building sales and distribution network in the US markets in the past four years, the benefits of which have started accruing now. We foresee the same thing happening with Dr Reddy’s going forward.

    At Rs 834, the stock is trading 32.2 times our expected FY05 earnings. While the last three quarters for the company have been terrible on both revenue growth as well as profitability fronts, we believe that the worse may be over for the company. The investments in sales and distribution and R&D (basically on the ANDA front) are likely to start paying of dividends going forward. While we may see volatility in the stock price in the short term as decisions on some Para IV challenges are likely to come, we are positive on the company from the long-term perspective.

     

     

    Equitymaster requests your view! Post a comment on "Dr Reddy’s: A volatile story". Click here!

      
     

    More Views on News

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Dr Reddy's: Major Business Segments Come Under Pressure (Quarterly Results Update - Detailed)

    Sep 12, 2016

    Dr Reddy's has announced the results for first quarter of FY17 (1QFY17). The company has reported decline in the sales by 13.9% YoY while net profits declined by 79.8 % YoY.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    DR. REDDYS LAB SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK DR. REDDYS LAB

    • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    DR. REDDYS LAB - J.B.CHEMICALS COMPARISON

    Compare Company With Charts

    COMPARE DR. REDDYS LAB WITH

    MARKET STATS